Insight

The impact of post-remission G-CSF use in the phase 3 studies of venetoclax in AML

Courtney D. DiNardo/faculty.mdanderson.org

Dec 6, 2024, 15:22

The impact of post-remission G-CSF use in the phase 3 studies of venetoclax in AML

Mohamed Benlazar, Professor of Hematology at Sidi Bel Abbès University Hospital, shared a post on X:

“The impact of post-remission G-CSF use in the phase 3 studies of venetoclax combination treatments in patients with newly diagnosed AML |American Journal of Hematology | Blood Research Journal | Wiley Online Library.”

The impact of post-remission granulocyte colony-stimulating factor use in the phase 3 studies of venetoclax combination treatments in patients with newly diagnosed acute myeloid leukemia

Authors: Courtney D. DiNardo, Keith W. Pratz, Panayiotis Panayiotidis, Xudong Wei, Vladimir Vorobyev, Árpád Illés, Inho Kim, Vladimir Ivanov, Grace Ku, Catherine L. Miller, Meng Zhang, Fernando Tatsch, Jalaja Potluri, Xenia Schmidt, Christian Récher

venetoclax

Árpád Illés cancer Catherine L. Miller Christian Récher Courtney D. DiNardo Fernando Tatsch Grace Ku Inho Kim Jalaja Potluri Keith W. Pratz Meng Zhang OncoDaily Oncology Panayiotis Panayiotidis venetoclax Vladimir Ivanov Vladimir Vorobyev Xenia Schmidt Xudong Wei

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Special Coverage